LIM Kinase Regulation of Actin Dynamics in Cancer Cells

The LIM kinases (LIMK1 and LIMK2) occupy a central position in the control of actin filament turnover, acting downstream of Rho family GTPases and upstream of the actin-severing protein cofilin. By phosphorylating cofilin, LIMKs inhibit filament disassembly, thereby promoting the formation of stress fibres and focal adhesions that underlie cell shape, motility and division. In cancer cells, aberrant activation of Rho, Rac and Cdc42 pathways leads to elevated LIMK activity, enhanced cofilin phosphorylation and stabilisation of actin networks that facilitate invasion and metastasis.

Dysregulation of LIMK expression and activity is frequently observed across a spectrum of malignancies. Overexpression of LIMK1 correlates with increased tumour cell migration and poor prognosis, while imbalanced LIMK1/LIMK2 ratios can modulate oncogenic programmes such as Wnt–β-catenin signalling and epithelial–mesenchymal transition. Structural insights into LIMK regulatory domains and the emergence of selective small-molecule inhibitors have begun to inform therapeutic strategies aimed at restoring proper actin dynamics and impairing cancer cell dissemination.

Research from Nature Portfolio

Recent structural studies have elucidated the autoregulatory function of the PDZ domain in LIMK2. A high-resolution crystal structure revealed an atypical peptide-binding surface and a conserved distal patch that governs kinase activation independent of the canonical activation-loop phosphorylation. Mutagenesis of this surface impaired LIMK activity in cellular assays, highlighting a novel target for allosteric modulation of actin remodelling.

Investigations into dietary bioactive compounds have demonstrated that diallyl disulfide (DADS) downregulates LIMK1 expression and reduces cofilin phosphorylation in colon cancer cells. Treatment with DADS suppressed migration and invasion in vitro and attenuated tumour growth in vivo, suggesting a utility for targeting the LIMK–cofilin axis with low-toxicity agents.

LIM Kinase Regulation of Actin Dynamics in Cancer Cells publication trend

The graph below shows the total number of articles in lim kinase regulation of actin dynamics in cancer cells across all publications each year (not limited to Nature Index journals).

Technical terms

LIM kinase: A serine/threonine kinase that regulates actin dynamics by phosphorylating cofilin and other substrates.

Cofilin: An actin-binding protein that disassembles filaments and whose activity is inhibited by phosphorylation.

PDZ domain: A protein interaction module that mediates assembly and autoregulation of kinases through specific binding surfaces.

Epithelial–mesenchymal transition (EMT): A cellular programme in which epithelial cells acquire motile mesenchymal traits to facilitate invasion.

References

1. Autoregulation of the LIM kinases by their PDZ domain. Nature Communications (2023).
2. LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. Cells (2023).
3. Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Molecular Cancer (2011).
4. Imbalanced LIMK1 and LIMK2 expression leads to human colorectal cancer progression and metastasis via promoting β-catenin nuclear translocation. Cell Death & Disease (2018).
5. Downregulation of LIMK1–ADF/cofilin by DADS inhibits the migration and invasion of colon cancer. Scientific Reports (2017).